Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-cash Items (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-cash Items for 3 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 61.94% to $12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Dec 2025, up 61.94% year-over-year, with the annual reading at $12.5 million for FY2025, 61.94% up from the prior year.
  • Non-cash Items for Q4 2025 was $12.5 million at Kura Oncology, down from $41.0 million in the prior quarter.
  • The five-year high for Non-cash Items was $49.6 million in Q1 2023, with the low at $7.7 million in Q4 2024.
  • Average Non-cash Items over 3 years is $39.3 million, with a median of $44.6 million recorded in 2023.
  • The sharpest move saw Non-cash Items tumbled 79.23% in 2024, then surged 61.94% in 2025.
  • Over 3 years, Non-cash Items stood at $37.1 million in 2023, then crashed by 79.23% to $7.7 million in 2024, then soared by 61.94% to $12.5 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $12.5 million, $41.0 million, and $43.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.